Citius Pharmaceuticals Inc (NASDAQ:CTXR)

1.17
BATS BZX Real-Time Price
As of 12:49pm ET
 +0.01 / +0.86%
Today’s Change
0.83
Today|||52-Week Range
2.25
-24.03%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$175.4M

Company Description

Citius Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to people suffering from hemorrhoids, NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome, and I/ONTAK, a protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL). The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.

Contact Information

Citius Pharmaceuticals, Inc.
11 Commerce Drive
Cranford New Jersey 07016
P:(908) 967-6677
Investor Relations:

Employees

Shareholders

Individual stakeholders8.42%
Mutual fund holders5.33%
Other institutional5.05%

Top Executives

Leonard L. MazurChairman & Chief Executive Officer
Gary F. TalaricoExecutive Vice President-Operations
Jaime BartushakChief Financial & Business Officer
Alan LaderVice President-Clinical Operations
Myron S. CzuczmanChief Medical Officer & Executive Vice President